Pulse Biosciences Inc (PLSE) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The PRECISE-BTN study is a prospective trial run by Pulse Biosciences, Inc. to test its nPulse Vybrance Percutaneous Electrode System in patients with symptomatic benign thyroid nodules. The goal is to confirm early human data and see how well the treatment eases symptoms and improves quality of life after ablation.
The intervention is a device-based ablation procedure using the nPulse Vybrance system. It is meant to shrink or disable benign thyroid nodules that cause pressure, discomfort, or cosmetic issues without needing full thyroid surgery.
The study is interventional with a single treatment arm and no randomization or placebo group. All enrolled adults receive the same device treatment, and the main purpose is to assess safety, feasibility, and symptom relief in real-world hospital settings.
The trial is listed as recruiting, signaling active site start-up and patient enrollment. The record was first submitted in December 2025, and the most recent update was filed on April 13, 2026, showing the protocol and status have been refreshed for investors to track.
As clinical evidence builds, positive data could support broader adoption of minimally invasive thyroid ablation, which may lift sentiment around PLSE and its platform. Investors should watch for early readouts versus surgery and radiofrequency ablation players, as success could position Pulse Biosciences as a niche device rival in thyroid care.
The PRECISE-BTN study remains active with updated information, and investors can review further details on the ClinicalTrials portal.